IQP-VV-102 (L-arabinose/grape marc)(IQP-VV-102 (L-arabinose/grape marc))

概要

基本信息

药物类型

中药

别名-

靶点-

作用机制-

治疗领域

内分泌与代谢疾病

在研适应症

肥胖

非在研适应症-

原研机构

InQpharm Group

在研机构

InQpharm Group

非在研机构-

最高研发阶段临床3期

首次获批日期-

最高研发阶段(中国)-

特殊审评-

登录后查看时间轴

关联

100 项与 IQP-VV-102 (L-arabinose/grape marc) 相关的临床结果

登录后查看更多信息

100 项与 IQP-VV-102 (L-arabinose/grape marc) 相关的转化医学

登录后查看更多信息

100 项与 IQP-VV-102 (L-arabinose/grape marc) 相关的专利（医药）

登录后查看更多信息

2

项与 IQP-VV-102 (L-arabinose/grape marc) 相关的文献（医药）

2016-01-01·Evidence-Based Complementary and Alternative Medicine

Corrigendum to “IQP‐VV‐102, a Novel Proprietary Composition for Weight Reduction: A Double‐Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety”

作者: Alt, Felix ; Grube, Barbara ; Bongartz, Udo

[This corrects the article DOI: 10.1155/2015/413075.].

2015-01-01·Evidence-Based Complementary and Alternative Medicine4区 · 医学

IQP-VV-102, a Novel Proprietary Composition for Weight Reduction: A Double-Blind Randomized Clinical Trial for Evaluation of Efficacy and Safety

4区 · 医学

ArticleOA

作者: Alt, Felix ; Grube, Barbara ; Bongartz, Udo

The individual ingredients in IQP-VV-102 have demonstrated promising effects in reducing sugar and starch digestion, which potentially leads to weight loss. The trial objective was to evaluate the safety and efficacy of IQP-VV-102 in reducing body weight in overweight and obese subjects. 120 overweight and obese individuals aged 18 to 60 years were randomly assigned to 2 treatment arms (IQP-VV-102 and placebo). The trial was conducted in 2 study centres in Berlin, Germany. The primary efficacy analysis was conducted on 117 subjects (IQP-VV-102:N=54; placebo:N=59), comparing the weight loss effect at baseline and 12 weeks after randomization. There was a statistically significant reduction in mean body weight of 3.29 kg (SD 2.30) in the IQP-VV-102 group compared to 0.83 kg (SD 2.00) in the placebo groupp<0.001. There were no serious or product-related adverse events that were reported over the combined period of 14 weeks. The findings suggested that IQP-VV-102 is effective and safe in body weight reduction in overweight and obese individuals in the short term. The study is registered under clinicaltrials.gov asNCT01681069.

100 项与 IQP-VV-102 (L-arabinose/grape marc) 相关的药物交易

登录后查看更多信息